• Mashup Score: 12

    New DAPA-CKD trial analyses have confirmed the outstanding renoprotective benefits of sodium–glucose co-transporter 2 inhibitors, independently of the presence of diabetes or the stage of kidney disease. Moreover, the non-steroidal mineralocorticoid receptor antagonist finerenone provides renal and cardiovascular protection in diabetic kidney disease when combined with…

    Tweet Tweets with this article
    • New 'Year in Review' online! Paola Fioretto & Roberto Pontremoli discuss data from clinical trials and therapeutic options for #DiabeticKidneyDisease in 2021. https://t.co/L48YwZB0uL https://t.co/ZJiDGTMBbi

  • Mashup Score: 29

    Available data suggest that the prevalence and incidence of kidney stones is increasing; however, much of this variation might result from differences in approaches used to identify stone formers. This Review describes the need for a classification system to facilitate use of consistent terminology and enable meaningful comparisons of the burden of kidney stone disease across different…

    Tweet Tweets with this article
    • Progression and pathways of kidney stone disease. https://t.co/VSnAXV002z https://t.co/cP2rYGXAJh